JBM  Vol.5 No.10 , October 2017
Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly women, presents several clinical manifestations and has no known exact cause. The skin is one of the organs that can be affected, with subacute cutaneous lupus erythematosus (SCLE) being one of the classifications according to cutaneous lupus erythematosus lesions. SCLE is commonly found in young to middle age women and carries characteristics related to sun exposure. In this report, there is a rare case of a male and elderly patient that presents SCLE subgroup initially asymptomatic, with subsequent appearance of macular skin lesions and vitiligo appearance. This is an important case to alert health professionals that the disease can manifest itself and open its clinical profile even in patients of sex and unusual ages.
Cite this paper: Martins, D. , Miguel, T. , dos Anjos, N. , Filho, S. , Paladino, V. , Miguel, B. , Miguel, V. , da Costa, D. and de Melo Pino, L. (2017) Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report. Journal of Biosciences and Medicines, 5, 25-33. doi: 10.4236/jbm.2017.510003.

[1]   Danchenko, N., Satia, J.A. and Anthony MS. (2006) Epidemiology of Systemic Lupus Erythematosus: A Comparison of Worldwide Disease Burden. Lupus, 15, 308-318.

[2]   Lisnevskaia, L., Murphy, G. and Isenberg, D. (2014) Systemic Lupus Erythematosus. Lancet, 384, 1878-1888.

[3]   Muscal, E. and Brey, R.L. (2010) Neurological Manifestations of Systemic Lupus Erythematosus in Children and Adults. Neurologic clinics, 28, 61-73.

[4]   Gottschalk, T.A., Tsantikos, E. and Hibbs, M.L. (2015) Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Frontiers in Immunology, 6, 550.

[5]   Szczech, J., Rutka, M., Samotij, D., Zalewska, A. and Reich, A. (2016) Clinical Characteristics of Cutaneous Lupus Erythematosus. Advances in Dermatology and Allergology/Postepy Dermatologiii Alergologii, 33, 13-17.

[6]   Marks, S.D. and Tullus, K. (2012) Autoantibodies in Systemic Lupus Erythematosus. Pediatric Nephrology, 27, 1855-1868.

[7]   Moura Filho, J.P., Peixoto, R.L., Martins, L.G., et al. (2014) Lupus Erythematosus: Considerations about Clinical, Cutaneous and Therapeutic Aspects. Anais Brasileiros de Dermatologia, 89, 118-125.

[8]   Vera-Recabarren, M.A., Garcia-Carrasco, M., Ramos-Casals, M. and Herrero, C. (2010) Cutaneous Lupus Erythematosus: Clinical and Immunological Study of 308 Patients Stratified by Gender. Clinical and Experimental Dermatology, 35, 729-735.

[9]   Biazar, C., Sigges, J., Nikolaos, P., et al. (2013) Cutaneous Lupus Erythematosus: First Multicenter Database Analysis of 1002 Patients from the European Society of Cutaneous Lupus Erythematosus (EULECS). Autoimmunity Reviews, 12, 444-454.

[10]   Gronhagen, C.M., Fored, C.M., Granath, F. and Nyberg, F. (2011) Cutaneous Lupus Erythematosus and the Association with Systemic Lupus Erythematosus: A Population-Based Cohort of 1088 Patients in Sweden. British Journal of Dermatology, 164, 1335-1341.

[11]   Okon, L.G. and Werth, V.P. (2013) Cutaneous Lupus Erythematosus: Diagnosis and Treatment. Best Practice & Research Clinical Rheumatology, 27, 391-404.

[12]   Freire, E.A.M., Souto, L.M. and Ciconelli, R.M. (2011) Medidas de avaliacao em lúpus eritematoso sistêmico. [Assessment Measures in Systemic Lupus Erythematosu.] Revista Brasileira de Reumatologia, 51, 75-80.

[13]   Petri, M., Orbai, A.M., Alarcón, G.S., et al. (2012) Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology, 64, 2677-2686.

[14]   Vera-Recabarren, M.A., Garcia-Carrasco, M., Ramos-Casals, M. and Herrero, C. (2010) Comparative Analysis of Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus: Clinical and Immunological Study of 270 Patients. British Journal of Dermatology, 162, 91-101.

[15]   Kuhn, A., Gensch, K., Haust, M., et al. (2011) Photoprotective Effects of a Broad-Spectrum Sunscreen in Ultraviolet-Induced Cutaneous Lupus Erythematosus: A Randomized, Vehicle-Controlled, Double-Blind Study. Journal of the American Academy of Dermatology, 64, 37-48.

[16]   Sticherling, M. (2011) Update on the Use of Topical Calcineurin Inhibitors in Cutaneous Lupus Erythematosus. Biologics: Targets & Therapy, 5, 21-31.

[17]   Obermoser, G., Sontheimer, R.D. and Zelger, B. (2010) Overview of Common, Rare and Atypical Manifestations of Cutaneous Lupus Erythematosus and Histopathological Correlates. Lupus, 19, 1050-1070.

[18]   Vasquez, R., Wang, D., Tran, Q.P., et al. (2012) A Multi-Center, Cross-Sectional Study on Quality of Life in Cutaneous Lupus Erythematosus. British Journal of Dermatology, 168, 145-153.

[19]   Postal, M., Costallat, L.T. and Appenzeller, S. (2012) Biological Therapy in Systemic Lupus Erythematosus. International Journal of Rheumatology, 9, 578-641.

[20]   Kuhn, A., Ruland, V. and Bonsmann, G. (2011) Cutaneous Lupus Erythematosus: Update of Therapeutic Options Part I. Journal of the American Academy of Dermatology, 65, 179-193.

[21]   Chang, A.Y. and Werth, V.P. (2011) Treatment of Cutaneous Lupus. Current Rheumatology Reports, 13, 300-307.

[22]   Kuhn, A., Ochsendorf, F. and Bonsmann, G. (2010) Treatment of Cutaneous Lupus Erythematosus. Lupus, 19, 1125-1136.

[23]   Verma, S.M., Okawa, J., Propert, K.J. and Werth, V.P. (2014) The Impact of Skin Damage Due to Cutaneous Lupus on Quality of Life. British Journal of Dermatology, 170, 315-321.

[24]   Uva, L., Miguel, D., Pinheiro, C., Freitas, J.P., Marques Gomes, M. and Filipe, P. (2012) Cutaneous Manifestations of Systemic Lupus Erythematosus. Autoimmune Diseases, 2012, Article ID: 834291.

[25]   Mellor-Pita, S., Citores, M.J., Castejon, R., Yebra-Bango, M., Tutor-Ureta, P., Rosado, S., et al. (2009) Monocytes and T Lymphocytes Contribute to a Predominance of Interleukin 6 and Interleukin 10 in Systemic Lupus Erythematosus. Cytometry Part B: Clinical Cytometry, 76, 261-270.

[26]   Sandholdt, L., Laurinaviciene, R. and Bygum, A. (2014) Proton Pump Inhibitor-Induced Subacute Cutaneous Lupus Erythematosus. The British Journal of Dermatology, 170, 342-351.

[27]   Aggarwal, N. (2016) Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. Drugs—Real World Outcomes, 3, 145-154.

[28]   Chang, A.Y., Piette, E.W., Foering, K.P., Tenhave, R.R., Okawa, J. and Werth, V.P. (2011) Response to Antimalarials in Cutaneous Lupus Erythematosus: A Prospective Analysis. Archives of Dermatology, 147, 1261-1267.

[29]   Frances, C., Cosnes, A., Duhaut, P., et al. (2012) Low Blood Concentration of Hydroxychloroquine in Patients with Refractory Cutaneous Lupus Erythematosus: A French Multicenter Prospective Study. Archives of Dermatology, 148, 479-484.

[30]   Chang, A.Y., Ghazi, E., Okawa, J. and Werth, V.P. (2013) Quality of Life Differences between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus. JAMA Dermatology, 149, 104-106.

[31]   Gronhagen, C.M., Fored, C.M., Linder, M., et al. (2012) Subacute Cutaneous Lupus Erythematosus and Its Association with Drugs: A Population-Based Matched Case-Control Study of 234 Patients in Sweden. British Journal of Dermatology, 167, 296-305.